^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Non-nucleoside reverse transcriptase inhibitor

    Related drugs:
    8d
    CABO-LA: Switch From Oral Therapy to Long-acting Injectable Cabotegravir + Rilpivirine (clinicaltrials.gov)
    P=N/A, N=50, Not yet recruiting, Pontificia Universidad Catolica de Chile | Trial completion date: Apr 2025 --> May 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date • HEOR
    10d
    PK, Safety Study of 90-Day Use of Vaginal Rings Containing Dapivirine and Levonorgestrel (clinicaltrials.gov)
    P1/2, N=40, Completed, International Partnership for Microbicides, Inc. | Active, not recruiting --> Completed
    Trial completion
    16d
    ELDORADO: DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection (clinicaltrials.gov)
    P3, N=610, Not yet recruiting, ANRS, Emerging Infectious Diseases | Trial completion date: Apr 2027 --> Nov 2027 | Initiation date: Apr 2024 --> Nov 2024 | Trial primary completion date: Apr 2026 --> Nov 2026
    Trial completion date • Trial initiation date • Trial primary completion date • Head-to-Head
    29d
    A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants (clinicaltrials.gov)
    P1, N=180, Recruiting, ViiV Healthcare | N=60 --> 180
    Enrollment change
    29d
    LOVER60: Long Acting Cabotegravir Plus Rilpivirine in People Living with HIV-1 Aged ≥ 60 Years for 24 (clinicaltrials.gov)
    P4, N=120, Not yet recruiting, Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
    New P4 trial
    |
    CD4 (CD4 Molecule)
    1m
    The Expand Study-Pharmacist Administered Long Acting Cabotegravir + Rilpivirine to Expand Access for People With HIV (clinicaltrials.gov)
    P=N/A, N=164, Not yet recruiting, MetroHealth Medical Center
    New trial
    1m
    A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediatric Studies (clinicaltrials.gov)
    P2, N=48, Active, not recruiting, Janssen Sciences Ireland UC | Trial primary completion date: Dec 2030 --> Jun 2027
    Trial primary completion date • Combination therapy
    1m
    DORASPEP: "Observational Study on Tolerability and Observance of Post-exposure Prophylaxis With Doravirine in HIV Viral Risk" (clinicaltrials.gov)
    P=N/A, N=226, Completed, Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba | Active, not recruiting --> Completed
    Trial completion
    2ms
    IMPALA: Improving HIV-1 Control in Africa with Long Acting Antiretrovirals (clinicaltrials.gov)
    P3, N=540, Active, not recruiting, MRC/UVRI and LSHTM Uganda Research Unit | Recruiting --> Active, not recruiting | Phase classification: P3b --> P3 | Trial completion date: Nov 2025 --> Mar 2026 | Trial primary completion date: Nov 2024 --> Apr 2025
    Enrollment closed • Phase classification • Trial completion date • Trial primary completion date
    2ms
    Efavirenz: New Hope in Cancer Therapy. (PubMed, Cureus)
    In addition to its anti-cancer properties, efavirenz has the advantage of being a well-established and relatively inexpensive medication with a favorable safety profile. If proven effective, efavirenz could offer a cost-effective therapeutic option, which is an intriguing direction that warrants further investigation.
    Review • Journal
    |
    FASN (Fatty acid synthase)
    |
    efavirenz
    2ms
    Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics (clinicaltrials.gov)
    P1/2, N=20, Recruiting, ViiV Healthcare | Trial completion date: Jun 2027 --> May 2028 | Trial primary completion date: Jul 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    2ms
    A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants (clinicaltrials.gov)
    P1, N=60, Recruiting, ViiV Healthcare | Trial primary completion date: Feb 2026 --> Oct 2026
    Trial primary completion date
    2ms
    Pharmacokinetics of Plasma Doravirine Once Daily Over 72 Hours Following Drug Intake Cessation in Healthy Volunteers (clinicaltrials.gov)
    P1, N=24, Completed, Chelsea and Westminster NHS Foundation Trust | N=14 --> 24
    Enrollment change
    2ms
    TLATOANI: Change in Body Weight and BMI in PWH with DOR/3TC/TDF Compared with INSTI (clinicaltrials.gov)
    P4, N=108, Recruiting, Instituto Mexicano del Seguro Social
    New P4 trial
    3ms
    Single Dose Pharmacokinetics of Doravirine in HIV-infected Pregnant Women (clinicaltrials.gov)
    P1, N=10, Recruiting, University of North Carolina, Chapel Hill | Trial completion date: Sep 2024 --> Jul 2025 | Trial primary completion date: Jun 2024 --> Mar 2025
    Trial completion date • Trial primary completion date
    3ms
    SUPLA: Outcomes of the PLHIV With Suboptimal Viral Suppression to Injectable Long-acting Antiretrovirals (clinicaltrials.gov)
    P3, N=40, Recruiting, Chang Gung Memorial Hospital | Not yet recruiting --> Recruiting
    Enrollment open • Adherence
    3ms
    The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE (clinicaltrials.gov)
    P3, N=310, Active, not recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting --> Active, not recruiting | Trial completion date: Dec 2026 --> Aug 2026 | Trial primary completion date: Jun 2025 --> Sep 2024
    Enrollment closed • Trial completion date • Trial primary completion date
    3ms
    Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social Needs (clinicaltrials.gov)
    P2, N=50, Recruiting, Yale University | Not yet recruiting --> Recruiting
    Enrollment open
    4ms
    CABO-CHANCE: A Real-life Study of the Use of Cabotegravir Plus Rilpivirine Long-acting in ART-experienced Pre-treated People With HIV (clinicaltrials.gov)
    P=N/A, N=287, Active, not recruiting, University Hospital Virgen de las Nieves
    New trial
    4ms
    SUPLA: Outcomes of the PLHIV With Suboptimal Viral Suppression to Injectable Long-acting Antiretrovirals (clinicaltrials.gov)
    P3, N=40, Not yet recruiting, Chang Gung Memorial Hospital
    New P3 trial • Adherence
    4ms
    PUSH: Peer Behavioral Activation Utilization to Address Structural Racism and Discrimination and Improve HIV Outcomes in High-Risk, Substance-Using Populations (clinicaltrials.gov)
    P=N/A, N=186, Not yet recruiting, University of Maryland, Baltimore
    New trial
    4ms
    Randomized, Open Label Safety Trial of Dapivirine Vaginal Ring and Oral TRUVADA® Use in Pregnancy (clinicaltrials.gov)
    P3, N=1105, Completed, National Institute of Allergy and Infectious Diseases (NIAID) | Active, not recruiting --> Completed | Phase classification: P3b --> P3
    Trial completion • Phase classification
    4ms
    PK, Safety Study of 90-Day Use of Vaginal Rings Containing Dapivirine and Levonorgestrel (clinicaltrials.gov)
    P1/2, N=40, Active, not recruiting, International Partnership for Microbicides, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    4ms
    Relative Bioavailability Trial of Dapivirine Ring-004 and Ring-008 (clinicaltrials.gov)
    P1, N=124, Completed, International Partnership for Microbicides, Inc. | Active, not recruiting --> Completed | Trial completion date: Apr 2024 --> Jul 2024
    Trial completion • Trial completion date
    4ms
    Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR Study (clinicaltrials.gov)
    P3, N=93, Completed, ViiV Healthcare | Trial primary completion date: Apr 2023 --> Sep 2023
    Trial primary completion date • Patient reported outcomes
    5ms
    Study of Novel Antiretrovirals in Participants With HIV-1 (clinicaltrials.gov)
    P1, N=49, Completed, Gilead Sciences | Active, not recruiting --> Completed | Trial completion date: Mar 2027 --> Mar 2024 | Trial primary completion date: Mar 2027 --> Mar 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    5ms
    Impact of efavirenz on hormone-positive breast cancer survival in women living with HIV. (PubMed, AIDS)
    Survival between women with estrogen-receptor positive breast cancer taking efavirenz (n = 38) and nonefavirenz regimens (n = 51) were compared. The 5-year overall-survival was 48.9% [95% confidence interval (CI) 33.0-72.2 and 51.1% (95% CI 34.0-76.8)] in the efavirenz and nonefavirenz groups, respectively suggesting efavirenz is unlikely driving poorer survival in women living with HIV and estrogen-receptor positive breast cancer.
    Journal
    |
    ER (Estrogen receptor)
    |
    efavirenz
    5ms
    EPIC: Evaluation of Pharmacokinetic Drug-drug Interactions Between Hormonal Contraceptives and Doravirine-containing ART Among Women Living With HIV in South Africa (clinicaltrials.gov)
    P4, N=108, Completed, University of Alabama at Birmingham | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Feb 2024 | Trial primary completion date: Jun 2024 --> Feb 2024
    Trial completion • Trial completion date • Trial primary completion date
    5ms
    A Study of a Rilpivirine Extended-Release Suspension in Healthy Participants (clinicaltrials.gov)
    P1, N=126, Completed, Janssen Research & Development, LLC | Active, not recruiting --> Completed
    Trial completion
    5ms
    IM-CAPABLE: IMplementation of CAB+RPV LA for People With HIV in Non-Metropolitan Areas (clinicaltrials.gov)
    P=N/A, N=55, Recruiting, University of Nebraska | Not yet recruiting --> Recruiting
    Enrollment open • Adherence
    5ms
    Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study (clinicaltrials.gov)
    P2, N=97, Completed, ViiV Healthcare | Phase classification: P2b --> P2
    Phase classification
    5ms
    IM-CAPABLE: IMplementation of CAB+RPV LA for People With HIV in Non-Metropolitan Areas (clinicaltrials.gov)
    P=N/A, N=55, Not yet recruiting, University of Nebraska
    New trial • Adherence
    5ms
    Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age (clinicaltrials.gov)
    P1/2, N=90, Recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Dec 2026 --> Jul 2027 | Trial primary completion date: Nov 2024 --> Apr 2025
    Trial completion date • Trial primary completion date
    5ms
    Study of Novel Antiretrovirals in Participants With HIV-1 (clinicaltrials.gov)
    P1, N=49, Active, not recruiting, Gilead Sciences | Recruiting --> Active, not recruiting | N=110 --> 49 | Trial completion date: Dec 2024 --> Mar 2027 | Trial primary completion date: Dec 2024 --> Mar 2027
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    6ms
    A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants (clinicaltrials.gov)
    P1, N=60, Recruiting, ViiV Healthcare | Trial completion date: Nov 2025 --> Nov 2027 | Trial primary completion date: Nov 2025 --> Feb 2026
    Trial completion date • Trial primary completion date
    6ms
    GLACIER: Study Using CABENUVA™ for the Treatment of Human Immunodeficiency Virus (HIV)-1, Administered in Infusion Centers (IC) or Alternate Sites of Administration (ASA) in the United States (U.S.) (clinicaltrials.gov)
    P4, N=44, Completed, ViiV Healthcare | Active, not recruiting --> Completed
    Trial completion
    6ms
    The use of PD-1 functional knockout rats to study idiosyncratic adverse reactions to nevirapine. (PubMed, Toxicol Sci)
    The treated PD-1m/m rats developed more severe liver injury than PD-1-/- mice, but in contrast to expectations, they did not develop a skin rash. Functional knockouts provide a unique tool to study the mechanisms of IDRs.
    Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1)
    6ms
    More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents (clinicaltrials.gov)
    P1/2, N=168, Active, not recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting --> Active, not recruiting
    Enrollment closed
    6ms
    Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social Needs (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, Yale University
    New P2 trial
    6ms
    DeLiTE: Can INSTI-associated Weight Gain be Halted or Reversed With a Switch to Doravirine/Lamivudine/Tenofovir DF? (clinicaltrials.gov)
    P4, N=4, Terminated, University Health Network, Toronto | N=25 --> 4 | Trial completion date: Dec 2024 --> Mar 2024 | Enrolling by invitation --> Terminated | Trial primary completion date: Aug 2024 --> Mar 2024; enrollment futility
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    6ms
    PANTER: Patient-Reported Outcomes in Real-life of Cabotegravir and Rilpivirine (clinicaltrials.gov)
    P=N/A, N=280, Not yet recruiting, University Paris 7 - Denis Diderot
    New trial • Patient reported outcomes
    6ms
    Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study:Uptake, Outcome, and Risk Factors for Treatment Failures (clinicaltrials.gov)
    P=N/A, N=600, Recruiting, University of Zurich
    New trial • Real-world evidence • Real-world
    |
    CD4 (CD4 Molecule)